Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40


Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.

Divya V, Pushpa VL, Sarithamol S, Manoj KB.

J Mol Graph Model. 2018 Jun;82:48-58. doi: 10.1016/j.jmgm.2018.04.001. Epub 2018 Apr 14.


Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2-Mediated Multi-Drug Resistance in Cancer Cells.

Gupta P, Zhang YK, Zhang XY, Wang YJ, Lu KW, Hall T, Peng R, Yang DH, Xie N, Chen ZS.

Cell Physiol Biochem. 2018;45(4):1515-1528. doi: 10.1159/000487578. Epub 2018 Feb 19.


Anticancer evaluation and molecular modeling of multi-targeted kinase inhibitors based pyrido[2,3-d]pyrimidine scaffold.

Elzahabi HSA, Nossier ES, Khalifa NM, Alasfoury RA, El-Manawaty MA.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):546-557. doi: 10.1080/14756366.2018.1437729.


Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach.

Rondla R, PadmaRao LS, Ramatenki V, Haredi-Abdel-Monsef A, Potlapally SR, Vuruputuri U.

Comput Biol Chem. 2017 Dec;71:224-229. doi: 10.1016/j.compbiolchem.2017.11.005. Epub 2017 Nov 14.


Bovine Hemoglobin Derived Peptide Asn-Phe-Gly-Lys Inhibits Pancreatic Cancer Cells Metastasis by Targeting Secreted Hsp90α.

Wang Y, Zhang T, Zhang H, Yang H, Li Y, Jiang Y.

J Food Sci. 2017 Dec;82(12):3005-3012. doi: 10.1111/1750-3841.13962. Epub 2017 Oct 30.


Discovery of a class of diheteroaromatic amines as orally bioavailable CDK1/4/6 inhibitors.

Fu Y, Tang S, Su Y, Lan X, Ye Y, Zha C, Li L, Cao J, Chen Y, Jiang L, Huang Y, Ding J, Geng M, Huang M, Wan H.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5332-5336. doi: 10.1016/j.bmcl.2017.09.050. Epub 2017 Oct 16.


Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKA.

Oh TI, Lee YM, Nam TJ, Ko YS, Mah S, Kim J, Kim Y, Reddy RH, Kim YJ, Hong S, Lim JH.

Int J Mol Sci. 2017 Sep 29;18(10). pii: E2074. doi: 10.3390/ijms18102074.


SKLB188 inhibits the growth of head and neck squamous cell carcinoma by suppressing EGFR signalling.

Barzegar M, Ma S, Zhang C, Chen X, Gu Y, Shang C, Jiang X, Yang J, Nathan CA, Yang S, Huang S.

Br J Cancer. 2017 Oct 10;117(8):1154-1163. doi: 10.1038/bjc.2017.298. Epub 2017 Sep 5.


Curcumin: Synthesis optimization and in silico interaction with cyclin dependent kinase.

Ahmed M, Abdul Qadir M, Imtiaz Shafiq M, Muddassar M, Hameed A, Nadeem Arshad M, Asiri AM.

Acta Pharm. 2017 Sep 1;67(3):385-395. doi: 10.1515/acph-2017-0023.


Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.

Chohan TA, Chen JJ, Qian HY, Pan YL, Chen JZ.

Mol Biosyst. 2016 Apr;12(4):1250-68. doi: 10.1039/c5mb00860c. Epub 2016 Feb 17.


BFD-22 a new potential inhibitor of BRAF inhibits the metastasis of B16F10 melanoma cells and simultaneously increased the tumor immunogenicity.

Ferreira AK, Pasqualoto KF, Kruyt FA, Palace-Berl F, Azevedo RA, Turra KM, Rodrigues CP, Ferreira AC, Salomón MA, de Sá Junior PL, Farias CF, Figueiredo CR, Tavares LC, Barbuto JA, Jorge SD.

Toxicol Appl Pharmacol. 2016 Mar 15;295:56-67. doi: 10.1016/j.taap.2016.02.008. Epub 2016 Feb 10.


Discovery of pyrrolospirooxindole derivatives as novel cyclin dependent kinase 4 (CDK4) inhibitors by catalyst-free, green approach.

Kamal A, Mahesh R, Nayak VL, Babu KS, Kumar GB, Shaik AB, Kapure JS, Alarifi A.

Eur J Med Chem. 2016 Jan 27;108:476-485. doi: 10.1016/j.ejmech.2015.11.046. Epub 2015 Dec 2.


Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion.

Xie XQ, Yang P, Zhang Y, Zhang P, Wang L, Ding Y, Yang M, Tong Q, Cheng H, Ji Q, McGuire T, Yuan W, Cheng T, Gao Y.

Sci Rep. 2015 Dec 18;5:18115. doi: 10.1038/srep18115.


Analysing the Effect of Mutation on Protein Function and Discovering Potential Inhibitors of CDK4: Molecular Modelling and Dynamics Studies.

N N, Zhu H, Liu J, V K, C GP, Chakraborty C, Chen L.

PLoS One. 2015 Aug 7;10(8):e0133969. doi: 10.1371/journal.pone.0133969. eCollection 2015.


Marine steroids as potential anticancer drug candidates: In silico investigation in search of inhibitors of Bcl-2 and CDK-4/Cyclin D1.

Saikia S, Kolita B, Dutta PP, Dutta DJ, Neipihoi, Nath S, Bordoloi M, Quan PM, Thuy TT, Phuong DL, Long PQ.

Steroids. 2015 Oct;102:7-16. doi: 10.1016/j.steroids.2015.06.012. Epub 2015 Jun 22.


The anticancer activity of the substituted pyridone-annelated isoindigo (5'-Cl) involves G0/G1 cell cycle arrest and inactivation of CDKs in the promyelocytic leukemia cell line HL-60.

Saleh AM, Aljada A, El-Abadelah MM, Taha MO, Sabri SS, Zahra JA, Aziz MA.

Cell Physiol Biochem. 2015;35(5):1943-57. doi: 10.1159/000374003. Epub 2015 Mar 27.


Cell cycle regulation and apoptotic cell death in experimental colon carcinogenesis: intervening with cyclooxygenase-2 inhibitors.

Saini MK, Sanyal SN.

Nutr Cancer. 2015;67(4):620-36. doi: 10.1080/01635581.2015.1015743. Epub 2015 Mar 31.


Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.

Zheng J, Kong H, Wilson JM, Guo J, Chang Y, Yang M, Xiao G, Sun P.

PLoS One. 2014 Apr 10;9(4):e93704. doi: 10.1371/journal.pone.0093704. eCollection 2014.


Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).

Reddy MV, Akula B, Cosenza SC, Athuluridivakar S, Mallireddigari MR, Pallela VR, Billa VK, Subbaiah DR, Bharathi EV, Vasquez-Del Carpio R, Padgaonkar A, Baker SJ, Reddy EP.

J Med Chem. 2014 Feb 13;57(3):578-99. doi: 10.1021/jm401073p. Epub 2014 Jan 24.

Supplemental Content

Loading ...
Support Center